USSTOCK.TODAY
Regular Market
Log in Sign up

Phio Pharmaceuticals Corp. Announces PH-762 Program Progress and Third Quarter Financial Results

Newsfile Corp. +3 · ·by G4L

PHIO
PHIO Phio Pharmaceuticals Corp
$0.81 -3.11%
View chart & analysis →
  1. 1Phio Pharmaceuticals Corp. successfully completed key development milestones to initiate the Phase 2b clinical stage of the PH-762 program.
  2. 2The company recorded $3 million in research and development expenses for the three months ended September 30, 2026.
  3. 3This represents a 159% increase in research and development expenses compared to the three months ended September 30, 2025.

So what's the key point?

Phio Pharmaceuticals Corp. successfully completed the next stage of research for developing a new drug. Research expenses reached $3 million, which is a significant increase from last year.

Source Newsfile Corp. +3 · View original ↗

Related 3-line summaries

Pio Pharmaceutical to Participate in Renmark Virtual Roadshow Newsfile Corp. +1 · Jul 24Rigel Pharmaceuticals Records $72.3 Million in Net Product Sales for Q3 2026 The Motley Fool +1 · 5d agoOscar Health reports Q3 earnings beating estimates and raises annual guidance Earnings Whispers +2 · 5d ago
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news